腫瘍の微小環境を調節するオステオポントンの多面的な役割
PubMedで要約を見る
まとめ
この要約は機械生成です。オステオポントンは腫瘍の微小環境にある非腫瘍細胞に影響を与え,がんの進行と免疫に影響を与えます. これらの相互作用を理解することで 癌の新たな治療戦略が生まれます
科学分野
- 腫瘍学
- 免疫学
- 細胞生物学
背景
- オステオポントンは,がんの進行に関与する重要な細胞外マトリックスタンパク質です.
- 腫瘍細胞は,患者の結果と治療反応に影響を与えるストロマ成分と相互作用する.
研究 の 目的
- 固体がんにおける非腫瘍細胞におけるオステオポントンの役割を検討する.
- ストロマ細胞に対するオステオポントンの影響に関する現象的およびメカニズム的洞察を探求する.
主な方法
- 非腫瘍細胞におけるオステオポントンの役割に焦点を当てた文献レビュー.
- オステオポントンの先天性および適応性免疫細胞の調節に関する分析.
- オステオポントンが構造的ストロマ細胞に及ぼす影響の検討.
主要な成果
- オステオポントンは様々な免疫細胞 (NK細胞,中性細胞,マクロファージ,DC細胞,MDSC細胞,B細胞,T細胞) に作用する.
- オステオポントンは構造的ストロマ細胞 (線維細胞,内皮細胞,脂肪細胞) を調節する.
- これらの相互作用は,腫瘍形成と転移に大きな影響を及ぼします.
結論
- オステオポントンのストロマ細胞の調節は,がんの進行において多軸的役割を果たします.
- オステオポントン/ストロマル媒介経路の理解は,新しい診断と治療戦略につながる.
- これらの経路をターゲットにすることで 癌の再発を治療する新たな道が開かれます
関連する概念動画
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

